SCHEMBL29393322

SCHEMBL29393322

CC(C)C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 13/20 0.46
▸ BACE2 Q9Y5Z0 3/20 0.46
▸ CTSD P07339 1/20 0.45
▸ PTPN1 P18031 3/20 0.44
▸ FOLH1 Q04609 2/20 0.43
▸ ERAP2 Q6P179 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31375132 0.97 FOLH1 (0.45) BACE1BACE2CTSDPTPN1FOLH1
SCHEMBL29531673 0.97 FOLH1 (0.45) BACE1BACE2CTSDPTPN1FOLH1
SCHEMBL29939815 0.97 FOLH1 (0.45) BACE1BACE2CTSDPTPN1FOLH1
SCHEMBL30974137 0.93 BACE1 (0.49) BACE1BACE2CTSDPTPN1ERAP2
SCHEMBL29680113 0.92 BACE1 (0.48) BACE1BACE2CTSDPTPN1
SCHEMBL29833296 0.91 PTPN1 (0.46) BACE1BACE2CTSDPTPN1ERAP2
SCHEMBL30688995 0.91 BACE1 (0.45) BACE1BACE2CTSDPTPN1FOLH1
SCHEMBL29886675 0.91 BACE1 (0.40) BACE1BACE2CTSDERAP2
SCHEMBL7599791 0.90 ERAP2 (0.44) BACE1BACE2CTSDPTPN1FOLH1
SCHEMBL7599777 0.90 ERAP2 (0.44) BACE1BACE2CTSDPTPN1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243502-A1 HIGH EXPRESSION VECTOR INCLUDING STRONG RECOMBINANT PROMOTER AND/OR TERMINATOR FOR MASS-PRODUCING PROTEIN OF INTEREST IN PLANT, AND METHOD FOR MASS-PRODUCING PROTEIN OF INTEREST USING SAME POSTECH Research and Business Development Foundation (KR) 2025-07-31 — — US claimed
US-12357685-B2 Vaccine composition for preventing rabies, and preparation method thereof BIOAPPLICATIONS INC. (KR) 2025-07-15 — — US claimed
US-12234262-B1 Vaccinia virus recombinant A33R protein and kit for diagnosing antibodies against orthopoxvirus comprising the same Republic Of Korea (Defense Acquisition Program Administration) (KR) 2025-02-25 — — US claimed
CN-118871589-A High expression vector comprising strong recombinant promoter and/or terminator for mass production of target protein from plant and mass production method of target protein using the same 浦项工科大学校产学协力团 2024-10-29 — — CN claimed
US-20240350614-A1 VACCINE FOR PREVENTING AFRICAN SWINE FEVER, COMPRISING AFRICAN SWINE FEVER VIRUS-DERIVED ANTIGEN PROTEIN BIOAPPLICATIONS INC. (KR) 2024-10-24 — — US claimed
EP-4393505-A1 VACCINE FOR PREVENTING AFRICAN SWINE FEVER, COMPRISING AFRICAN SWINE FEVER VIRUS-DERIVED ANTIGEN PROTEIN Bioapplications Inc. (KR) 2024-07-03 — — EP claimed
CN-112135630-B Swine fever vaccine composition and preparation method thereof 巴伊沃爱普有限公司 2024-02-27 — — CN claimed
US-11845945-B2 Recombinant vector for expressing target protein in plant cell BIOAPPLICATIONS INC. (KR) 2023-12-19 — — US claimed
WO-2023177114-A1 HIGH EXPRESSION VECTOR INCLUDING STRONG RECOMBINANT PROMOTER AND/OR TERMINATOR FOR MASS-PRODUCING PROTEIN OF INTEREST IN PLANT, AND METHOD FOR MASS-PRODUCING PROTEIN OF INTEREST USING SAME 포항공과대학교 산학협력단 2023-09-21 — — WO claimed
WO-2023171835-A1 METHOD FOR REMOVING ENDOTOXIN LPS BY USING RECOMBINANT PROTEIN COMPRISING SUSHI DOMAIN OF FACTOR C PRODUCED IN PLANT 포항공과대학교 산학협력단 2023-09-14 — — WO claimed
CN-111565747-B Antigen fused to porcine FC fragment and vaccine composition comprising the same 巴伊沃爱普有限公司 2023-08-15 — — CN claimed
US-20230218729-A1 RECOMBINANT PROTEIN FOR NEUTERING OR SPAYING ANIMAL, AND VACCINE COMPOSITION COMPRISING SAME BIOAPPLICATIONS INC. (KR) 2023-07-13 — — US claimed
US-20230173044-A1 RECOMBINANT PROTEIN FOR REMOVING BOAR TAINT AND VACCINE COMPOSITION COMPRISING THE SAME BIOAPPLICATIONS INC. (KR) 2023-06-08 — — US claimed
WO-2023027402-A1 VACCINE FOR PREVENTING AFRICAN SWINE FEVER, COMPRISING AFRICAN SWINE FEVER VIRUS-DERIVED ANTIGEN PROTEIN 주식회사 바이오앱 2023-03-02 — — WO claimed
EP-4129326-A1 RECOMBINANT PROTEIN FOR NEUTERING OR SPAYING ANIMAL, AND VACCINE COMPOSITION COMPRISING SAME Bioapplications Inc. (KR) 2023-02-08 — — EP claimed
CN-114196699-B Method for increasing extracellular secretion of plant cell recombinant protein 猎境(嘉兴)生物科技有限公司 2022-12-20 — — CN claimed
CN-115066256-A Recombinant protein for animal sterilization or castration and vaccine composition comprising the same 巴伊沃爱普有限公司 2022-09-16 — — CN claimed
US-11434496-B2 Recombinant vector comprising BiP fragment and preparation method of recombinant proteins using thereof BIOAPPLICATIONS INC. (KR) 2022-09-06 — — US claimed
US-20220235366-A1 RECOMBINANT VECTOR FOR EXPRESSING TARGET PROTEIN IN PLANT CELL BIOAPPLICATIONS INC. (KR) 2022-07-28 — — US claimed
US-11279943-B2 Recombinant vector for expressing target protein in plant cell BIOAPPLICATIONS INC. (KR) 2022-03-22 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279943-B2 Recombinant vector for expressing target protein in plant cell ENGASE, GLG1, RPS27A BACE1 4157/4885BACE2 2876/4885CTSD 2613/4885
US-20220235366-A1 RECOMBINANT VECTOR FOR EXPRESSING TARGET PROTEIN IN PLANT CELL ENGASE, GLG1, RPS27A BACE1 4157/4885BACE2 2876/4885CTSD 2613/4885
US-11845945-B2 Recombinant vector for expressing target protein in plant cell ENGASE, GLG1, RPS27A BACE1 4157/4885BACE2 2876/4885CTSD 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback